Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson says schizophrenia injection works better than oral drug

Johnson and Johnson says schizophrenia injection works better than oral drug

8th May 2008

A new treatment for schizophrenia could prolong the time it takes for a patient to relapse, a study suggests.

The risperidone long-acting injection (RLAI) showed results that were favourable against the current oral drug quetiapine, Johnson & Johnson (J&J) said.

The company presented its results at the 161st annual meeting of the American Psychiatric Association in Washington DC.

Study investigator professor Wolfgang Gaebel from Heinrich-Heine University in Dusseldorf said: “This study provides compelling evidence that RLAI offers a significant benefit to people with schizophrenia in delaying the time to relapse.”

Almost half of schizophrenia patients do not stay on their oral medication and this results in a relapse of their symptoms, J&J said, while those in receipt of the RLAI took longer to relapse.

RLAI is manufactured by Alkermes and marketed in the UK by Janssen-Cilag, one of the 190 J&J healthcare companies worldwide.

According to the Royal College of Psychiatrists, schizophrenia symptoms can be divided into positive and negative, where the former includes hallucinations and the latter includes depression.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.